Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely
Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.
You may also be interested in...
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.